OBJECTIVE: Women with a history of preeclampsia are at an increased risk of developing premature cardiovascular disease due to endothelial dysfunction. Faulty cyclic guanosine-3' ,5'-monophosphate (cGMP) signaling secondary to the up-regulation of phosphodiesterase (PDE) isoenzymes is seen in both cardiovascular disease and preeclampsia. We hypothesize that sildenafil, a PDE5 inhibitor, may attenuate the expected cardiac changes associated with the selective reduced uterine perfusion pressure (SRUPP) rat model of hypertensive disorders in pregnancy STUDY DESIGN: Pregnant Sprague-Dawley rats were divided into one of 4 groups: sham (n¼12), SRUPP (n¼12), sham with sildenafil (sham+S) (n¼10), and SRUPP with sildenafil (SRUPP+S) (n¼11). On gestational day (GD) 13 the rats underwent maternal echocardiography. On GD 14, rats were anesthetized with 2% isoflurane and the abdomen entered through a midline vertical incision. Uterine and utero-ovarian arteries were identified and surgically isolated. In the SRUPP and SRUPP+S groups, silver clips (0.102mm internal diameter) were placed on the aforementioned vessels bilaterally. The sham and sham+S groups' vessels were solely isolated. The rats were returned to their home cages after surgery. From GD14 to GD20 the SRUPP+S and sham+S groups were fed 20g/day of rat chow with sildenafil at an inclusion rate of 625mg/kg diet with the goal to deliver 50mg/kg/day (sildenafil 12.5mg/d). The remaining groups were given 20g of similar rat chow without sildenafil. On GD 20, all pregnant rats underwent repeat maternal echocardiography. Analysis of Variance (ANOVA) with post hoc multiple comparison tests were used to analyze data. A p value of <0.05 determined statistical significance. RESULTS: There was no significant difference in echocardiogram parameters among the groups on GD 13. On GD 20, the cardiac output (CO) in the SRUPP group (64.63 + 2.03 mL/min) was significantly increased compared to the sham surgery group (49.35 + 3.58 mL/min)(p¼ 0.008). Additionally, the stroke volume differed significantly between the SRUPP surgery group (166.29 + 6.19uL OBJECTIVE: ACOG revised its guidelines for managing preeclampsia with severe features (SPE) in 2013 to recommend expectant management (EM) as opposed to immediate delivery (ID) in appropriate women given evidence that EM improved neonatal outcomes without significant maternal harm. We sought to pragmatically compare maternal and neonatal outcomes in women with SPE before and after implementation of these guidelines. STUDY DESIGN: We conducted a retrospective cohort study of all women with SPE delivering non-anomalous live singletons 23-34 weeks at a single tertiary care center from 2013-2017. Patients were categorized as pre-guideline (1/2013-12/2015) or post-guideline adoption (1/2016-12/2017 e managed per ACOG guidelines). Primary outcomes included maternal and neonatal composite morbidity; secondary outcomes included composite components (Table) , length of stay, birthweight, and delivery gestational age (GA). Groups were compared with Student's t-test, Chi-square, and Wilcoxon rank sum tests; odds ratios (95% CIs) were calculated and adjusted for covariates. Yearly composite outcome rates were compared using Cochran-Armitage trend test. Subgroup analysis of pre-and post-guideline cohorts excluding women ineligible for EM by ACOG guidelines was planned. We estimated a sample size of 250 per group would provide 80% power at a ¼ 0.05 to detect a 50% reduction in neonatal morbidity from a 21.5% pre-guideline rate. RESULTS: From 2013-2017, 543 women with SPE were identified: 278 (51%) pre-guideline and 265 (49%) post-guideline change. Baseline characteristics were similar between groups except marital status and higher admission blood pressures in the post-guideline group (Table). There were no significant differences in delivery GA, maternal or neonatal composite morbidity between groups (Table) . There were no significant differences in composite maternal or neonatal morbidity over time (Figure) . Subgroup analysis excluding women ineligible for EM was consistent with the primary analysis. CONCLUSION: Overall perinatal outcomes were similar before and after implementation of new SPE management guidelines at our institution. Prospective studies are needed to evaluate guideline compliance or if benefits are limited to subsets of this population, e.g. earlier or later GAs.
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